Trial Profile

Phase 1 study of COYA 302

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COYA-302 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

20 Jun 2024 According to a Coya media release, company expands sponsored research collaboration with Houston Methodist Research Institute along with funding from the Johnson Center for Cellular Therapeutics to advance regulatory T cell exosome platform into the clinic.
09 May 2024 According to a Coya media release, updated biomarker data has been presented at the 2nd Annual Johnson Center Symposium in late April 2024.
06 Mar 2024 Results published in the Coya media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com